Biopharmaceutical company Cassava Sciences, along with founder Remi Barbier and former Senior Vice President of Neuroscience Lindsay Burns, PhD, will pay more than $40 million to settle allegations related to misleading claims about a clinical trial for its Alzheimer’s disease treatment.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
